20:17 , Nov 19, 2018 |  BC Extra  |  Preclinical News

RNAi method targets placenta directly to treat preeclampsia

In a Nature Biotechnology study , researchers from University of Massachusetts Medical School and colleagues reported that siRNA targeting sFLT1 could help treat preeclampsia. The results suggest the RNAi modality could be used to directly...
07:00 , Jun 23, 2016 |  BC Innovations  |  Tools & Techniques

Home is in the placenta

Many drug developers have avoided stepping into what they see as the high risk area of pregnancy-associated complications, leaving diseases such as preeclampsia and fetal growth restriction with little innovation and few treatment options. By...
07:00 , Apr 21, 2016 |  BC Innovations  |  Product R&D

A1M for preeclampsia

A poor understanding of disease biology and a challenging development pathway have kept most drug developers away from the serious pregnancy complication preeclampsia, but A1M Pharma AB has a new approach with a first-in-class therapy...
07:00 , Mar 24, 2016 |  BC Innovations  |  Product R&D

Liver-bound

Ionis Pharmaceuticals Inc. is retooling its antisense technology with a sugar-based conjugate that boosts uptake into liver cells. By tapping the power of GalNAc sugars to latch onto hepatocyte receptors, the company believes it can...
08:00 , Dec 15, 2014 |  BC Week In Review  |  Company News

Alnylam pharmaceuticals news

Alnylam outlined plans to focus its RNAi pipeline on genetic medicine, cardio-metabolic diseases and hepatic infectious diseases. Clinical genetic medicine programs include Phase III transthyretin-mediated amyloidosis (ATTR) candidates patisiran and revusiran as well as Phase...
07:00 , Oct 16, 2014 |  BC Innovations  |  Targets & Mechanisms

Alnylam interrupts preeclampsia

Preeclampsia often involves overactivation of the renin-angiotensin system that regulates blood pressure, but inhibiting the pathway is not possible because it would be toxic to the fetus. Alnylam Pharmaceuticals Inc. has developed an siRNA conjugate...
07:00 , Oct 6, 2014 |  BC Week In Review  |  Clinical News

Alnylam preclinical data

In a rat model of preeclampsia, subcutaneous ALN-AGT led to >90% knockdown of maternal angiotensinogen (AGT) in the liver with no detectable evidence of fetal drug exposure. ALN-AGT also significantly reduced mean arterial blood pressure...
08:00 , Feb 14, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Non-small cell lung cancer (NSCLC) Angiotensinogen (AGT); angiotensin-converting enzyme (ACE) Patient tissue and mouse studies suggest ACE inhibitors could help treat NSCLC in patients with...
08:00 , Feb 8, 2010 |  BioCentury  |  Strategy

Out from Down Under

A dearth of funding often forces Australian companies to out-license products too early in development to get any meaningful revenues out of them, because they can't afford to get them to market by themselves. By...
08:00 , Jan 8, 2007 |  BioCentury  |  Strategy

Thinking globally

Thinking globally Company Notes Bionomics (ASX:BNO) Acquired French company Neurofit in 2005, giving it preclinical CNS development capabilities Biota (ASX:BTA) Acquired U.S. antiviral company NuMax in 2001 Bone Medical (ASX:BNE) Osteoporosis and arthritis company with...